Capivasertib in combination with fulvestrant for HR-positive, HER2-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alteration

Agency for Care Effectiveness (ACE)
Record ID 32018015219
English
Details
Project Status: Completed
Year Published: 2026
URL for published report: https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidances/drug-guidance/capivasertib-in-combination-with-fulvestrant-for-hr-positive--her2-negative--locally-advanced-or-metastatic-breast-cancer-with-one-or-more-pik3ca-akt1-pten-alteration/
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Singapore
MeSH Terms
  • Breast Neoplasms
  • Antineoplastic Combined Chemotherapy Protocols
  • Antineoplastic Agents
  • Protein Kinase Inhibitors
  • Fulvestrant
Contact
Organisation Name: Agency for Care Effectiveness (ACE)
Contact Address: Ministry of Health, College of Medicine Building, 16 College Road, Singapore 169854
Contact Name: ACE_HTA@moh.gov.sg
Contact Email: ACE_HTA@moh.gov.sg
Copyright: Agency for Care Effectiveness (ACE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.